- Home
- STTK vs MEGI Comparison
STTK vs MEGI Comparison
Compare STTK & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STTK | MEGI |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.8M | 788.0M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STTK | MEGI |
|---|---|---|
| Price | $7.30 | $15.15 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 131.5K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $13.42 |
| 52 Week High | $8.33 | $15.89 |
Technical Indicators
Market Signals| Indicator | STTK | MEGI |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 46.33 |
| Support Level | $5.87 | $14.78 |
| Resistance Level | $7.75 | $15.46 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 55.08 | 30.85 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.